Close

Share this page

Philippines

Our Manila office opened in 2004, serving the third-largest pharmaceutical market in the ASEAN region. The Philippines is well positioned for future growth that will largely be driven by the government continuing to encourage the use of generics while improving the regulatory environment to attract foreign investment. In particular, clinical research into vaccinations used to prevent tropical diseases is an area that is bound to expand, due in part to the field having been neglected for many years and because of the availability of a large patient pool.


Fast Facts

Health Expenditure per Capita
(2018, US$)

$124

Source: Financing Global Health Database 2018

Population(2019)
 

108

million people

Source: The World Bank

Burden of Disease DALYs Causes % of Total DALYs
(2017, all ages/both sexes)

Ischemic heart disease (7.93%)

Neonatal disorders (7.54%)

Lower respiratory infections (7.08%)

Source: Institute Health Matrics and Evaluation GBD

NDA Approval Time

12

months



18

months




Features

Clinical trial regulations in the Philippines: application and protocol approval

Clinical trial regulations in the Philippines are now of the utmost importance. The number of clinical trials conducted has increased substantially over the years. In 2009 alone, the Philippines saw a 30.9% increase in clinical trials conducted ...

Neglected tropical diseases and rabies: the struggles of the Philippine government

The Philippines has long been plagued by neglected tropical diseases (NTDs) such as schistosomiasis, soil-transmitted helminthiasis, leptospirosis, dengue and rabies. Poorer rural communities are disproportionally impacted ...


Services Available in Philippines

We will tailor an ideal solution for your specific needs.

Contact Us